Not Yet Recruiting PHASE1 INTERVENTIONAL 1-arm NCT06652529

Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors (AROG4-01-01)

First in Human Phase 1 Dose Escalation and Expansion Clinical Trial to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of Intravenous AROG4-01 in Patients With Advanced Solid Tumors

Sponsor: Aromics Therapeutics

Conditions Colorectal Carcinoma Mesothelioma NSCLC (Advanced Non-small Cell Lung Cancer) Ovarian Cancer Solid Tumors (Phase 1)

Interventions AROG4-01

Updated 2 times since 2024 Last updated: Nov 5, 2024 Started: Jan 31, 2025 Primary completion: Dec 31, 2025 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06652529, this PHASE1 trial focuses on Colorectal Carcinoma and Mesothelioma and remains actively recruiting participants. Sponsored by Aromics Therapeutics, it has been updated 2 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

2 versions recorded

Dec 2024 — Present [monthly]

Not Yet Recruiting PHASE1
Nov 2024 — Dec 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aromics Therapeutics

Data source: Aromics Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.